Jan 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd
* Says unit Sunovion Pharmaceuticals Inc. (Sunovion) announced topline results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinsonâ€™s disease (PD) who experience motor fluctuations (OFF episodes)
* Study CTH-300 met its primary and key secondary endpoints, and the medicine was also generally well-tolerated by study participants
Source text in Japanese: goo.gl/sE7Qks
Further company coverage: (Beijing Headline News)
 